Search results
Results from the WOW.Com Content Network
Clenbuterol is approved for use in some countries as a bronchodilator for asthma. [medical citation needed] Clenbuterol is a β 2 agonist with some structural and pharmacological similarities to epinephrine and salbutamol, but its effects are more potent and longer-lasting as a stimulant and thermogenic drug.
For premium support please call: 800-290-4726 more ways to reach us
Adverse effects [ edit ] The adverse effect profile of bambuterol is similar to that of salbutamol , and may include fatigue , nausea , palpitations , headache , dizziness and tremor .
Trimbow is indicated for the maintenance treatment in adults with moderate to severe chronic obstructive pulmonary disease (COPD) and asthma who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta2-agonist or a combination of a long-acting beta2-agonist and a long-acting muscarinic antagonist.
Serious side effects may include worsening asthma, anaphylaxis, seizures, and heart problems. [5] Safety in pregnancy and breastfeeding is unclear. [ 6 ] Fluticasone, a corticosteroid , works by decreasing inflammation while salmeterol, a long-acting beta-adrenoceptor agonist (LABA), works by activating beta-2 adrenergic receptors .
Serious side effects are valid for all atypical antipsychotics and may include the potentially permanent movement disorder tardive dyskinesia, as well as neuroleptic malignant syndrome, an increased risk of suicide, angioedema, and high blood sugar levels, [10] although lurasidone is less likely to cause high blood sugar levels in most patients ...
The most common side effects of these drugs that led to withdrawals were mental disturbances, cardiac side effects, and drug abuse or drug dependence. Deaths were associated with seven products. [85] Ephedra was removed from the US market in 2004 over concerns that it raises blood pressure and could lead to strokes and death. [86]
The placebo-subtracted mean weight losses were 4.5%, 9.2% and 10.6% in the 0.25 mg, 0.5 mg and 1 mg dose groups, respectively. The weight loss seen in the Phase IIB trial was approximately double that produced by medications that had been approved (as of 2008) by the US Food and Drug Administration (FDA) for the treatment of obesity.